Automate Your Wheel Strategy on MESO
With Tiblio's Option Bot, you can configure your own wheel strategy including MESO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MESO
- Rev/Share 0.005
- Book/Share 0.4042
- PB 2.7489
- Debt/Equity 0.2734
- CurrentRatio 0.9578
- ROIC -0.1424
- MktCap 1410947780.0
- FreeCF/Share -0.0185
- PFCF -66.9537
- PE -12.2686
- Debt/Assets 0.193
- DivYield 0
- ROE -0.2195
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MESO | Jefferies | Buy | Hold | -- | -- | Dec. 23, 2024 |
| Upgrade | MESO | Maxim Group | Hold | Buy | -- | $12 | Sept. 24, 2024 |
| Upgrade | MESO | Jefferies | Hold | Buy | -- | -- | Aug. 29, 2024 |
News
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.
Read More
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government's announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs.
Read More
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.
Read More
Ryoncil® is Now Available for Purchase in the United States
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States.
Read More
Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Mesoblast Limited (NASDAQ:MESO ) Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Silviu Itescu - Chief Executive Officer & Managing Director Andrew Chaponnel - Interim Chief Financial Officer Marcelo Santoro - Chief Commercial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Michael Okunewitch - Maxim Group Silviu Itescu Good morning, everybody. I'm Silviu Itescu.
Read More
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Financial Results and Operational Update for Half-Year Ended December 31, 2024 Financial Results and Operational Update for Half-Year Ended December 31, 2024
Read More
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Mesoblast Limited (MESO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Dr. Gregory George MD PhD Joins Mesoblast Board
Published: February 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors.
Read More
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product Ryoncil® (remestemcel-L) is being highlighted at the 2025 Transplantation & Cellular Therapy Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR), the industry's premier conference taking place this week in Honolulu, HI.
Read More
About Mesoblast Limited (MESO)
- IPO Date 2010-01-20
- Website https://www.mesoblast.com
- Industry Biotechnology
- CEO Silviu Itescu FACP, FACRA, FRACP, MBBS
- Employees 73